bioLytical Pledges Support for Second International Workshop on HIV Treatment as Prevention
Richmond, B.C. – Oct. 28, 2011. In a show of support for the world leading HIV/AIDS research being undertaken in British Columbia, Canada, Canadian life sciences firm bioLytical Laboratories has pledged financial support for the Second International Workshop on HIV Treatment as Prevention.
The Workshop, to be held in Vancouver, British Columbia April 22nd – 25th 2012, will bring academic, policy, industry, and community representatives together to review new data and to identify priority areas for research and action related to the impact of combination antiretroviral therapy (ART) use among HIV infected individuals on the transmission of HIV infection. The event will serve as a focal point for researchers involved in Treatment as Prevention to share data, protocols and findings, and to foster an open collaborative environment regarding this important research.
I very much appreciate the support of bioLytical, commented a pioneer of the Treatment as Prevention strategy, Professor Julio Montaner, Director of the BC Centre for Excellence in HIV/AIDS and the St. Paul’s Hospital Foundation Chair in AIDS Research Professor of Medicine, at the University of British Columbia.
For the second year we are delighted to pledge our support for this important conference. The Treatment as Prevention strategy can produce long-term and transformative results for the treatment and prevention of HIV/AIDS said Colin MacGillivray, Chief Operating Officer & CFO, bioLytical Laboratories. We are very pleased that so many key players from around the world will gather and collaborate in British Columbia where the Treatment as Prevention strategy was pioneered and which is also the home province of bioLytical.
bioLytical Laboratories is the maker of the INSTI rapid HIV Antibody test, which is able to detect HIV antibodies in just one minute. Ease of use and speed to result allow many more tests to be administered and people to find out their results almost instantaneously.
First commercialized in 2006, the INSTI rapid HIV Antibody test has been extensively field-tested and is the only point-of-care rapid HIV Antibody test approved by Health Canada. INSTI also has European CE mark approval, and recently received U.S. Food and Drug Administration (FDA) approval.
Over two million INSTI tests have been conducted worldwide, and the test is an essential component of the $48 million, cutting-edge STOP HIV/AIDS pilot announced in British Columbia last year.
For more information, call bioLytical at 888-316-0351 or visit www.biolytical.com.
Laura Ballance Media Group